{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T20:38:07Z","timestamp":1778531887053,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102270","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T12:18:55Z","timestamp":1731673135000},"page":"102270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab"],"prefix":"10.1016","volume":"23","author":[{"given":"Alicia K.","family":"Morgans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-9611","authenticated-orcid":false,"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phoebe","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Hepp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice L.","family":"Willmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2986-6647","authenticated-orcid":false,"given":"Nancy N.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Mucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Sriteja Boppudi","family":"Naga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2024.102270_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10122","key":"10.1016\/j.clgc.2024.102270_bib0002","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"10031","key":"10.1016\/j.clgc.2024.102270_bib0003","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2024.102270_bib0004","unstructured":"Cancer Stat Facts: Bladder Cancer. National Institutes of Health. National Cancer Institute: Surveillance Epidemiology and End Results Program. 2021. Accessed June 3, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"issue":"3","key":"10.1016\/j.clgc.2024.102270_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102270_bib0006","doi-asserted-by":"crossref","first-page":"357.e11","DOI":"10.1016\/j.urolonc.2023.03.012","article-title":"Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced\/metastatic urothelial carcinoma by cisplatin-eligibility","volume":"41","author":"Morgans","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102270_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102072","article-title":"Clinical evidence for the first-line treatment of advanced urothelial carcinoma: current paradigms and emerging treatment options","volume":"89","author":"Koufopoulou","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.clgc.2024.102270_bib0008","first-page":"240","article-title":"Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis","volume":"27","author":"Hepp","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clgc.2024.102270_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103683","article-title":"Recent therapeutic advances in urothelial carcinoma: a paradigm shift in disease management","volume":"174","author":"Bellmunt","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102270_bib0010","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.3390\/curroncol30040277","article-title":"Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced\/metastatic urothelial carcinoma (la\/mUC)","volume":"30","author":"Bloudek","year":"2023","journal-title":"Curr Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2024.102270_bib0011","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the javelin bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clgc.2024.102270_bib0012","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clgc.2024.102270_bib0013","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1200\/JOP.2017.024224","article-title":"Use of electronic health record data for quality reporting","volume":"13","author":"Abernethy","year":"2017","journal-title":"J Oncol Pract"},{"issue":"16","key":"10.1016\/j.clgc.2024.102270_bib0014","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","volume":"3","author":"Ma","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.clgc.2024.102270_bib0015","unstructured":"FDA approves avelumab for urothelial carcinoma maintenance treatment. News release. US Food and Drug Administration; July 1, 2020. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment. Accessed June 18, 2024."},{"issue":"6","key":"10.1016\/j.clgc.2024.102270_bib0016","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2023.41.6_suppl.572","article-title":"Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la\/mUC) in the US","volume":"41","author":"Kearney","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102270_bib0017","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1200\/JCO.2023.41.6_suppl.483","article-title":"US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102270_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.8395","article-title":"Uptake of maintenance immunotherapy and changes in upstream treatment selection among patients with urothelial cancer","volume":"6","author":"Mamtani","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.clgc.2024.102270_bib0019","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1200\/JCO.2023.41.16_suppl.4567","article-title":"Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC)","volume":"41","author":"Moon","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102270_bib0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102270_bib0021","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/CLEP.S409791","article-title":"Benchmarking maintenance therapy survival in first-line platinum-based chemotherapy\u2013treated patients with advanced urothelial carcinoma using simulated disease modeling","volume":"15","author":"Galsky","year":"2023","journal-title":"Clin Epidemiol"},{"issue":"suppl 4","key":"10.1016\/j.clgc.2024.102270_bib0022","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.2024.42.4_suppl.560","article-title":"Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: real-world insights from The US Oncology Network","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2024.102270_bib0023","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2024.102270_bib0024","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102270_bib0025","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer V4.2024. 2024. \u00a9Accessed 18 June 2024. Referenced with permission from the NCCN. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"3","key":"10.1016\/j.clgc.2024.102270_bib0026","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/oncolo\/oyad267","article-title":"Evaluating oncologists' practice patterns and decision-making in locally advanced or metastatic urothelial carcinoma: the US Physician PARADIGM Study","volume":"29","author":"Gupta","year":"2024","journal-title":"Oncologist"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:20:17Z","timestamp":1753111217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1558767324002404"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102270","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102270"}}